Stay updated on Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Sign up to get notified when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.

Latest updates to the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedRevision indicator updated to v3.5.0, replacing the previous v3.4.3.SummaryDifference0.1%

- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedRevision tag updated from v3.4.2 to v3.4.3. No visible changes to study details, eligibility criteria, or locations.SummaryDifference0.1%

- Check44 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2; this is a minor platform update with no changes to study information. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check51 days agoChange Detected- Revision: v3.4.1 added; Revision: v3.4.0 removed.SummaryDifference0.1%

- Check66 days agoChange DetectedAdded UI text for glossary toggles (Show glossary, Hide glossary) and new policy/version labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0); removed the prior wording (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4).SummaryDifference0.3%

- Check74 days agoChange DetectedPage revision updated from v3.3.3 to v3.3.4.SummaryDifference0.1%

Stay in the know with updates to Nivolumab with 5-azacytidine in Childhood AML Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab with 5-azacytidine in Childhood AML Clinical Trial page.